Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a fully integrated mRNA solution to biopharmaceutical developers.
• The collaboration brings together Ethris’ comprehensive mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM RNA), minimal UTR and mRNA manufacturing technologies with Thermo Fisher’s industry-leading end-to-end GMP-compliant manufacturing capabilities.
• Broadening global access to Ethris’ comprehensive suite of mRNA technology platforms, the partners will facilitate the ability of biopharmaceutical developers to rapidly advance candidate mRNA medicines from research to clinical proof-of-concept.
• “Thermo Fisher Scientific has a long-standing track record of supporting the development of advanced therapies,” said Dr. Carsten Rudolph, CEO of Ethris.
• “By combining our clinically validated mRNA platforms with Thermo Fisher’s manufacturing expertise, we are creating a powerful offering for biopharma partners. This collaboration addresses the increasing demand for scalable, high-quality mRNA technologies and enables us to serve a broader set of collaborators worldwide.”
• ETH47, Ethris’ lead candidate, demonstrated positive pharmacodynamic effects in Phase 1 trials.
• Designed for nasal spray administration, targeting asthma exacerbations.
• Showed dose-dependent, localized production of interferon lambda with no systemic bioavailability.
• Activated downstream signaling, confirming functional activity of the expressed protein.
• SNIM RNAs allow repeated administration for sustained therapeutic protein production.
• Technology can replace or augment missing proteins, modulate disease progression, and support vaccine development.
• “Thermo Fisher is committed to supporting the rapid translation of breakthrough therapies into clinical application,” said Ben Castro, vice president and general manager, Large Molecule, Drug Substance, Thermo Fisher Scientific.
• “By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.”
Ethris’ SNIM RNA platform sets new standards for mRNA therapeutics by enabling safe, efficacious and stable drug products as well as scalable manufacturing, expanding the potential of mRNA medicines.
Ethris, a clinical-stage biotechnology company, has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies.